This cancer phenotype is characterized by a slower progression and requires a different approach to treatment than more aggressive subtypes (such as cancer with HER2 overexpression/amplification or triple negative breast cancer without HR or HER2 expression). Here, ERBB2 is linked to triple-negative breast carcinoma.